Education
About Us
Working with TipRanks
Follow Us
Pulmonx (LUNG)
NASDAQ:LUNG
LUNG Stock Chart & Stats
$1.64
-$0.17(-2.57%)
At close: 4:00 PM EST
$1.64
-$0.17(-2.57%)
Day’s Range― - ―
52-Week Range$1.31 - $9.37
Previous CloseN/A
Volume95.69K
Average Volume (3M)308.20K
Market Cap
$67.65M
Enterprise Value$47.66M
Total Cash (Recent Filing)$76.55M
Total Debt (Recent Filing)$56.56M
Price to Earnings (P/E)―
Beta1.04
Next Earnings
Feb 25, 2026EPS Estimate
-0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.34
Shares Outstanding41,247,032
10 Day Avg. Volume245,979
30 Day Avg. Volume308,202
Financial Highlights & Ratios
PEG Ratio0.47
Price to Book (P/B)3.09
Price to Sales (P/S)3.17
P/FCF Ratio-8.05
Enterprise Value/Market Cap0.70
Enterprise Value/Revenue0.52
Enterprise Value/Gross Profit0.71
Enterprise Value/Ebitda-0.88
Forecast
1Y Price Target
$4.10Price Target Upside150.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Executive LeadershipReturn of the original CEO and CFO brings experienced operators familiar with the business, which can stabilize decision-making and accelerate corrective actions to address past weaknesses.
Product EconomicsA solid product offering combined with strong gross margins provides management with room to improve profitability as operational challenges are resolved.
Revenue Momentum And Strategic PlanPreliminary revenue results that beat expectations, paired with a promised strategic plan to restore high-growth, support expectations for a clearer path to sustainable, profitable growth.
Bears Say
Guidance ResetA guidance cut to reset achievable targets increases near-term uncertainty and could weigh on sentiment until the new outlook and assumptions are fully communicated.
Sales Execution RiskUncertainty about whether underperforming territories reflect personnel issues or deeper structural problems creates risk to revenue recovery and the scalability of the commercial model.
Pulmonx News
LUNG FAQ
What was Pulmonx’s price range in the past 12 months?
Pulmonx lowest stock price was $1.31 and its highest was $9.37 in the past 12 months.
What is Pulmonx’s market cap?
Pulmonx’s market cap is $67.65M.
When is Pulmonx’s upcoming earnings report date?
Pulmonx’s upcoming earnings report date is Feb 25, 2026 which is in 23 days.
How were Pulmonx’s earnings last quarter?
Pulmonx released its earnings results on Nov 12, 2025. The company reported -$0.34 earnings per share for the quarter, beating the consensus estimate of -$0.422 by $0.082.
Is Pulmonx overvalued?
According to Wall Street analysts Pulmonx’s price is currently Undervalued.
Does Pulmonx pay dividends?
Pulmonx does not currently pay dividends.
What is Pulmonx’s EPS estimate?
Pulmonx’s EPS estimate is -0.4.
How many shares outstanding does Pulmonx have?
Pulmonx has 41,247,032 shares outstanding.
What happened to Pulmonx’s price movement after its last earnings report?
Pulmonx reported an EPS of -$0.34 in its last earnings report, beating expectations of -$0.422. Following the earnings report the stock price went down -18.878%.
Which hedge fund is a major shareholder of Pulmonx?
Currently, no hedge funds are holding shares in LUNG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pulmonx Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.10 (150.00% Upside)
$4.10 (150.00% Upside)
Hedge Fund Trend
Decreased
By 2.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $39.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 6.0%
Last 30 Days ▼ 6.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-74.30%
12-Months-Change
Fundamentals
Return on Equity
-73.73%
Trailing 12-Months
Asset Growth
-14.74%
Trailing 12-Months
Company Description
Pulmonx
Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.
LUNG Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed picture with some positive developments in international growth and gross margin improvement, but ongoing challenges in U.S. growth, rising expenses, persistent net loss, and decreasing cash reserves. The focus on execution and profitability suggests attempts to address these issues, but immediate growth strategies remain uncertain.View all LUNG earnings summariesLUNG Stock 12 Month Forecast
Average Price Target
$4.10
▲(150.00% Upside)
Technical Analysis
Apyx Medical
―
Xtant Medical Holdings
―
Sensus Healthcare
―
TELA Bio
―
Icecure Medical
―
Ownership Overview
12.81% Insiders
17.40% Mutual Funds
0.12% Other Institutional Investors
54.52% Public Companies and
Individual Investors